Brian M. Culley
President and CEO at Lineage Cell Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Lineage Cell Therapeutics Inc., 3 years.
Lineage Cell Therapeutics Inc.
Director · President and CEO
Chief executive roles
Lineage Cell Therapeutics Inc.
· President and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 12, 2026 | Lineage Cell Therapeutics Inc. | Open-market purchase | +15,000 | $1.63 | $24,450 |
| Feb 11, 2026 | Lineage Cell Therapeutics Inc. | Option exercise | +31,250 | — | — |
| Feb 11, 2026 | Lineage Cell Therapeutics Inc. | Shares withheld for tax | −12,869 | $1.80 | $23,164 |
| Dec 19, 2025 | Lineage Cell Therapeutics Inc. | Grant or award | +8,925 | — | — |
| Dec 19, 2025 | Lineage Cell Therapeutics Inc. | Shares withheld for tax | −334 | $1.68 | $561 |
| Feb 11, 2025 | Lineage Cell Therapeutics Inc. | Option exercise | +31,249 | — | — |
| Feb 11, 2025 | Lineage Cell Therapeutics Inc. | Shares withheld for tax | −12,547 | $0.65 | $8,156 |
| Nov 21, 2024 | Lineage Cell Therapeutics Inc. | Open-market purchase | +40,000 | $0.60 | $24,000 |
| May 24, 2024 | Lineage Cell Therapeutics Inc. | Open-market purchase | +10,000 | $1.05 | $10,500 |
| Feb 11, 2024 | Lineage Cell Therapeutics Inc. | Option exercise | +31,249 | — | — |
| Feb 11, 2024 | Lineage Cell Therapeutics Inc. | Shares withheld for tax | −12,806 | $1.08 | $13,830 |
| Feb 11, 2023 | Lineage Cell Therapeutics Inc. | Option exercise | +31,249 | — | — |
| Feb 11, 2023 | Lineage Cell Therapeutics Inc. | Shares withheld for tax | −12,744 | $1.35 | $17,204 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.